Home>Topics>>After 2 Drug Approvals, Can Supernus Deliver In 2013?
After 2 Drug Approvals, Can Supernus Deliver In 2013?
Healthcare Sector and Stocks Analysis from Seeking Alpha
Mon, 26 Nov 2012
By C.R. Jackson : Supernus Pharmaceuticals ( SUPN ) is developing a central nervous system ( CNS ) portfolio with proprietary extended release technologies. While most shareholders are investing in Supernus because of the strength of the company's epilepsy and attention deficit-hyperactivity ...
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.